COCH Envoy Medical Inc.

Subscribe to $COCH

Envoy Medical Inc.

Subscribe to $COCH

$COCH

Industrial Specialties

Health Care

IPO Year: 2021

Exchange: NASDAQ

Recent Analyst Ratings for Envoy Medical Inc.

Date	Price Target	Rating	Analyst
6/24/2024	$8.50	Buy	Ascendiant Capital Markets

See more ratings

Envoy Medical Inc. Press Releases

Fastest customizable press release news feed in the world

New CPT Codes for Totally Implantable Active Middle Ear Hearing Implants Go into Effect July 1, Unlocking New Opportunities for Envoy Medical
The Esteem(R) device by Envoy Medical is the only totally implantable active middle ear implant with FDA Approval currently on the marketWhite Bear Lake, Minnesota--(Newsfile Corp. - June 26, 2025) - Envoy Medical, Inc. (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that five Category III CPT codes for totally implantable active middle ear implants approved by the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel will be effective on July 1st 2025. CPT codes are used by healthcare professionals and insurers to identify, track, and pay for medical se
6/26/25 8:00:00 AM ET
$COCH
Industrial Specialties
Health Care
Life Sciences Investor Forum: Now Available for Online Viewing
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad
6/13/25 8:35:00 AM ET
$ATNM
$BPTH
$COCH
$IMNN
Biotechnology: Pharmaceutical Preparations
Health Care
Industrial Specialties
Medical/Nursing Services
Envoy Medical to Present at the Life Sciences Virtual Investor Forum June 12th
WHITE BEAR LAKE, Minn., June 11, 2025 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that Brent Lucas, CEO of Envoy Medical, will present live at the Life Sciences Virtual Investor Frum hosted by VirtualInvestorConferences.com, on June 12th, 2025. DATE: June 12th TIME: 3pm EasternLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th through the 17th This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the da
6/11/25 8:30:00 AM ET
$COCH
Industrial Specialties
Health Care
Life Sciences Investor Forum Agenda Announced for June 11th-12th
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co
6/10/25 2:38:09 PM ET
$ATNM
$BPTH
$COCH
$IMNN
Biotechnology: Pharmaceutical Preparations
Health Care
Industrial Specialties
Medical/Nursing Services
Envoy Medical's Pivotal Clinical Trial for Fully Implanted Acclaim(R) Cochlear Implant Remains On Track After First Month Follow-Up
Positive momentum from the trial's first stage encouraging Company to accelerate plans for expansion and commercializationWhite Bear Lake, Minnesota--(Newsfile Corp. - June 10, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that all 10 of the study participants in the first stage of the Company's pivotal clinical trial for the fully implanted Acclaim® Cochlear Implant have successfully completed their one-month follow-up visits. The investigational sites have reported that the visits are proceeding as expected. Due to the device's breakthr
6/10/25 8:30:00 AM ET
$COCH
Industrial Specialties
Health Care
Envoy Medical Achieves Clinical Trial Milestone and is Optimistic About Expansion into Final Stage of Trial
White Bear Lake, Minnesota--(Newsfile Corp. - May 13, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announces achieving the important milestone of successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. Brent Lucas, CEO of Envoy Medical commented: "We are excited to report the positive and meaningful progress of our pivotal clinical trial, which is currently on track and moving along as anticipated. We are optimistic we will be able to expand the study
5/13/25 9:15:00 AM ET
$COCH
Industrial Specialties
Health Care
Envoy Medical Reports on First Quarter 2025 Results
Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat
5/1/25 4:30:00 PM ET
$COCH
Industrial Specialties
Health Care
EdgarAgents Debuts EA34 Plugin at Centri Capital Conference to Simplify and Expedite Financial Filing Process for Mid-to-Microcap Companies
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- EdgarAgents (EA), a leading provider of simplified and efficient solutions that expedite U.S. Securities and Exchange Commission (SEC®) compliance filings, announces today the availability of EA34 Plugin, the company's newest user-centered technology-enabled solution. EA34 Plugin officially launches at the Centri Capital Conference in New York City at Nasdaq Global Headquarters. Powered by the latest inline eXtensible Business Reporting Language (iXBRL) — a global standard to share financial and business data electronically — and EDGAR® technology, EA34 Plugin was tailor-made as a "hybrid-service" financial content management collaboration pla
4/22/25 6:00:00 AM ET
$COCH
Industrial Specialties
Health Care
Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results
Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to
3/31/25 9:15:00 AM ET
$COCH
Industrial Specialties
Health Care
Hearing Device Coverage Clarification Act Reintroduced in House and Senate
Seek to clarify that certain hearing implants are prosthetics and therefore not subject to the hearing aid coverage exclusion, allowing for potential Medicare coverageWhite Bear Lake, Minnesota--(Newsfile Corp. - March 17, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced the reintroduction of the Hearing Device Coverage Clarification Act in both the U.S. House of Representatives and U.S. Senate. Representative Michelle Fischbach (R-MN) reintroduced the House version of the bill - H.R. 1921 - along with Representative Angie Craig (D-MN) on March 6, 2025. Senator Amy Klobuchar (D-MN)
3/17/25 9:25:00 AM ET
$COCH
Industrial Specialties
Health Care

Envoy Medical Inc.

Recent Analyst Ratings for Envoy Medical Inc.

Envoy Medical Inc. SEC Filings

Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Envoy Medical Inc.

Envoy Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

SEC Form 10-Q filed by Envoy Medical Inc.

SEC Form DEFA14A filed by Envoy Medical Inc.

SEC Form DEF 14A filed by Envoy Medical Inc.

Envoy Medical Inc. filed SEC Form 8-K: Shareholder Director Nominations

Envoy Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

Envoy Medical Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Patel Mona Chetan bought $3,675 worth of shares (2,500 units at $1.47), increasing direct ownership by 14% to 20,000 units (SEC Form 4)

Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

Chief Executive Officer Lucas Brent T. was granted 12,907 shares, increasing direct ownership by 6% to 216,485 units (SEC Form 4)

Director Brynelsen Charles bought $82,403 worth of shares (50,000 units at $1.65) (SEC Form 4)

SEC Form 4 filed by Director Taylor Glen A

Director Kantor Susan acquired 34,705 shares, increasing direct ownership by 80% to 77,887 units (SEC Form 4)

Large owner Anzu Spac Gp I Llc converted options into 1,028,986 shares and disposed of 2,028,986 shares (SEC Form 4)

SEC Form 4 filed by Director Taylor Glen A

SEC Form 4 filed by Chief Executive Officer Lucas Brent T.

Director Patel Mona Chetan bought $5,699 worth of shares (2,500 units at $2.28), increasing direct ownership by 50% to 7,500 units (SEC Form 4)

Envoy Medical Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Patel Mona Chetan bought $3,675 worth of shares (2,500 units at $1.47), increasing direct ownership by 14% to 20,000 units (SEC Form 4)

Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

Director Brynelsen Charles bought $82,403 worth of shares (50,000 units at $1.65) (SEC Form 4)

Director Patel Mona Chetan bought $5,699 worth of shares (2,500 units at $2.28), increasing direct ownership by 50% to 7,500 units (SEC Form 4)

Director Patel Mona Chetan bought $16,520 worth of shares (5,000 units at $3.30) (SEC Form 4)

Envoy Medical Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

Envoy Medical Inc. Press Releases

Fastest customizable press release news feed in the world

New CPT Codes for Totally Implantable Active Middle Ear Hearing Implants Go into Effect July 1, Unlocking New Opportunities for Envoy Medical

Life Sciences Investor Forum: Now Available for Online Viewing

Envoy Medical to Present at the Life Sciences Virtual Investor Forum June 12th

Life Sciences Investor Forum Agenda Announced for June 11th-12th

Envoy Medical's Pivotal Clinical Trial for Fully Implanted Acclaim(R) Cochlear Implant Remains On Track After First Month Follow-Up

Envoy Medical Achieves Clinical Trial Milestone and is Optimistic About Expansion into Final Stage of Trial

Envoy Medical Reports on First Quarter 2025 Results

EdgarAgents Debuts EA34 Plugin at Centri Capital Conference to Simplify and Expedite Financial Filing Process for Mid-to-Microcap Companies

Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results

Hearing Device Coverage Clarification Act Reintroduced in House and Senate

Envoy Medical Inc. Leadership Updates

Live Leadership Updates

Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

Envoy Medical to Host Fireside Chat Event December 7